Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

February 27, 2014

Las Vegas, Nevada

Scientific Agenda

1:00 pm

Welcome and Introductions

1:05 pm

Gary J. Schiller, MD, FACP

  • Risk stratification and treatment decisions in AML
  • FLT3 inhibitors in AML
  • Novel treatment strategies for AML
  • low and intermediate-1 risk MDS
  • Intermediate-2 and high risk MDS

1:30 pm

Q&A Session

1:35 pm

Myeloproliferative Neoplasms
Rueben A. Mesa, MD

  • Molecular biology of MPNs
  • JAK2 inhibitors
  • Beyond JAK2 inhibitors

1:55 pm

Q&A Session

2:00 pm

Chronic Myelocytic Leukemia
Neil Shah, MD, PhD

  • Selecting appropriate frontline therapy for CML
  • Managing long term TKI therapy in CML
  • T315I and other “resistant” mutations in CML

2:25 pm

Q&A Session

2:30 pm

Chronic Lymphocytic Leukemia
William G. Wierda, MD, PhD

  • Frontline regimens for fit and for elderly patients
  • BTK inhibitors and PI3K inhibitors
  • CART cells in CLL

2:55 pm

Q&A Session

3:00 pm

Coffee Break

3:20 pm

Aggressive Non-Hodgkins Lymphomas and Hodgkins Lymphoma
Morton Coleman, MD

  • Therapeutic Options for Early Stage Diffuse Large B-Cell Lymphoma
  • Advanced Stage DLBCL: Frontline and Relapsed Disease
  • Molecular Markers and Novel Targets for DLBC Lymphoma
  • Emerging Therapies for DLBC Lymphoma
  • Therapeutic options for early and advanced stage Hodgkins Lymphoma

3:40 pm

Q&A Session

3:45 pm

Indolent Lymphomas, Mantle Cell Lymphomas & T-Cell Lymphomas
Fredrick B. Hagemeister, MD

  • Frontline Therapy for Follicular Lymphomas
  • Novel Therapies for Advanced Follicular Lymphomas
  • Maintenance Therapies for Indolent Lymphomas
  • The Role of PI3K and BTK inhibitors
  • Frontline Therapy for Mantle Cell Lymphoma
  • The role of immunomodulatory agents in MCL
  • Advances in T-cell lymphoma therapy

4:10 pm

Q&A Session

4:15 pm

Frontline Therapy and Maintenance for Newly Diagnosed Multiple Myeloma
Jeffrey L. Wolf, MD

  • Transplant eligible versus transplant ineligible patients
  • Doublets versus Triplets
  • Integrating Novel Agents into Frontline Regimens
  • proteasome inhibitors and immunomodulatory agents
  • maintenance therapy

4:40 pm

Q&A Session

4:45 pm


4:55 pm

Advances in the Management of Relapsed/Refractory Multiple Myeloma
Robert Z. Orlowski, MD, PhD

  • Novel Proteasome Inhibitors
  • Novel Immunomodulatory Drugs
  • Monoclonal Antibodies for Myeloma
  • HDAC Inhibitors
  • HSP90, PI3K and Akt inhibitors
  • Kinesin Spindle Protein inhibitors

5:20 pm

Q&A Session

5:25 pm

Coagulation Disorders and Thrombophilia
Craig M. Kessler, MD

  • Emerging Science
  • Novel Agents
  • Thrombophilic Disorders

5:50 pm

Q&A Session

5:55 pm

Closing Remarks

6:00 pm